Key Metrics
CiteScore 

8.1
Eigenfactor 

0.001 - 0.005
Impact Factor 

5 - 10
SJR 

Q2Oncology

SNIP 

1.39
Recommended pre-submission checks
Powered by 

Topics Covered on Experimental Hematology and Oncology
Experimental Hematology and Oncology Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
DOAJ
SJR
| Overview | |
| Publisher | BMC |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | EUR 2590 | USD 2990 | GBP 2290 |
| Publication Time | 6 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2012 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC0 |
| OA statement | Visit website |
View less
Planning to publish in Experimental Hematology and Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Experimental Hematology and Oncology
Preclinical and clinical studies on CAR-NK cell therapy: latest update from 2025 ASH Annual Meeting
- 18 May 2026
- Experimental Hematology & Oncology
Hierarchies of resistance to DNA damage response inhibitors: from pathway restoration to replication stress tolerance.
- 11 May 2026
- Experimental hematology & oncology
Inhibition of protein kinase CK2 remodels the tumor immune microenvironment and sensitizes lung cancer to PD-L1 blockade.
- 9 May 2026
- Experimental hematology & oncology
ISX-TWIST1 reprograms CD47-inflammasome signaling to reshape the immune microenvironment in liver cancer.
- 4 May 2026
- Experimental hematology & oncology
Combining circulating tumor cell and circulating cell-free DNA analyses broadens clinical applicability of liquid biopsy in high grade serous tubo-ovarian carcinoma.
- 21 Apr 2026
- Experimental hematology & oncology
Metabolic drivers of genome instability in cancer: mechanisms and therapeutic opportunities.
- 18 Apr 2026
- Experimental hematology & oncology
Preclinical and clinical studies on CAR-NK cell therapy: latest update from 2025 ASH Annual Meeting
- 18 May 2026
- Experimental Hematology & Oncology
Hierarchies of resistance to DNA damage response inhibitors: from pathway restoration to replication stress tolerance.
- 11 May 2026
- Experimental hematology & oncology
Inhibition of protein kinase CK2 remodels the tumor immune microenvironment and sensitizes lung cancer to PD-L1 blockade.
- 9 May 2026
- Experimental hematology & oncology
ISX-TWIST1 reprograms CD47-inflammasome signaling to reshape the immune microenvironment in liver cancer.
- 4 May 2026
- Experimental hematology & oncology
Combining circulating tumor cell and circulating cell-free DNA analyses broadens clinical applicability of liquid biopsy in high grade serous tubo-ovarian carcinoma.
- 21 Apr 2026
- Experimental hematology & oncology
Metabolic drivers of genome instability in cancer: mechanisms and therapeutic opportunities.
- 18 Apr 2026
- Experimental hematology & oncology